[go: up one dir, main page]

IL160603A0 - C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals - Google Patents

C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals

Info

Publication number
IL160603A0
IL160603A0 IL16060302A IL16060302A IL160603A0 IL 160603 A0 IL160603 A0 IL 160603A0 IL 16060302 A IL16060302 A IL 16060302A IL 16060302 A IL16060302 A IL 16060302A IL 160603 A0 IL160603 A0 IL 160603A0
Authority
IL
Israel
Prior art keywords
derivatives
processes
preparation
systems
pharmaceuticals
Prior art date
Application number
IL16060302A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL160603A0 publication Critical patent/IL160603A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/17Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/20Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16060302A 2001-08-31 2002-08-17 C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals IL160603A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142663A DE10142663B4 (de) 2001-08-31 2001-08-31 C2-Disubstituierte Indan-1-ol-Systeme
PCT/EP2002/009203 WO2003020695A1 (de) 2001-08-31 2002-08-17 C2-disubstituierte indan-1-ol-systeme, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
IL160603A0 true IL160603A0 (en) 2004-07-25

Family

ID=7697234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16060302A IL160603A0 (en) 2001-08-31 2002-08-17 C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals

Country Status (11)

Country Link
US (1) US6982353B2 (es)
EP (1) EP1425264B1 (es)
JP (1) JP4250078B2 (es)
AT (1) ATE412630T1 (es)
AU (1) AU2002336982B2 (es)
CA (1) CA2458523A1 (es)
DE (2) DE10142663B4 (es)
IL (1) IL160603A0 (es)
MX (1) MXPA04001849A (es)
PE (1) PE20030362A1 (es)
WO (1) WO2003020695A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050564A (en) 1958-12-02 1962-08-21 Exxon Research Engineering Co Preparation of new hydroperoxides by the cooxidation of olefinic compounds and mercaptans
US3016349A (en) 1959-08-10 1962-01-09 Exxon Research Engineering Co Denitrogenation of petroleum
US3043824A (en) 1959-09-28 1962-07-10 Exxon Research Engineering Co Hydroperoxide and sulfoxide compounds
US3016348A (en) 1959-11-02 1962-01-09 Universal Oil Prod Co Manufacture and use of sulfided hydrocarbon purification catalyst
YU33726B (en) 1969-07-04 1978-02-28 Montedison Spa Process for cross-linking of plastomers
US5808062A (en) 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
PT729465E (pt) 1993-11-19 2003-06-30 Parke Davis & Co Derivados de pirona como inibidores de protease e agentes antivirais
US5622514A (en) 1995-06-30 1997-04-22 The Whitaker Corporation Coverless pin grid array socket
DE69629387T2 (de) * 1995-12-06 2004-06-24 Venantius Ltd. Dimere indan verbindungen und ihre pharmazeutische verwendung
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
US5985913A (en) 1996-11-29 1999-11-16 Osi Pharmaceuticals, Inc. Tetracyclic compounds for enhancing biosynthesis of erythropoietin, compositions containing same, and methods of use thereof
ATE246190T1 (de) 1996-12-31 2003-08-15 Reddys Lab Ltd Dr Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
EP0986530A1 (en) 1997-06-05 2000-03-22 Venantius Limited Indane compounds and their pharmaceutical use
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
DE19844547C2 (de) * 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142660A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de) 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142667B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142666A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142661B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142659A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Also Published As

Publication number Publication date
US20030181491A1 (en) 2003-09-25
ATE412630T1 (de) 2008-11-15
PE20030362A1 (es) 2003-06-02
EP1425264A1 (de) 2004-06-09
DE50212971D1 (de) 2008-12-11
US6982353B2 (en) 2006-01-03
MXPA04001849A (es) 2004-06-15
DE10142663B4 (de) 2004-08-19
JP4250078B2 (ja) 2009-04-08
EP1425264B1 (de) 2008-10-29
DE10142663A1 (de) 2003-03-27
CA2458523A1 (en) 2003-03-13
AU2002336982B2 (en) 2008-01-31
WO2003020695A1 (de) 2003-03-13
JP2005501902A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
MXPA04012965A (es) Inhibidores virales.
NO20052739L (no) CCR5-antagonister som medikamenter
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO1998056761A3 (en) Benzimidazole derivatives
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
AU2003297048A8 (en) Cyclohexyl compounds as ccr5 antagonists
NO20082496L (no) Pyrazinderivater
GB0112348D0 (en) Compounds
DE60205455T2 (de) Naphthyridinderivate
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
WO2004037166A3 (en) Therapeutic guanidines
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
IL160601A0 (en) Use of derivatives of c2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
IL160605A (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
MXPA04001853A (es) Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad.